Status:

COMPLETED

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

Lead Sponsor:

Lykos Therapeutics

Conditions:

Posttraumatic Stress Disorder

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective and reducing PTSD symptoms in veterans with chronic PTSD. The main question it aims to answer is: Do three do...

Detailed Description

This study is a randomized, double-blind, dose comparison study with an open-label cross-over segment that will assess the safety and efficacy of MDMA-assisted therapy in veterans with chronic PTSD. T...

Eligibility Criteria

Inclusion

  • Be diagnosed with chronic PTSD, duration of 6 months or longer resulting from traumatic experience during military service;
  • Have a CAPS score showing moderate to severe PTSD symptoms;
  • Have had at least one unsuccessful attempt at treatment for PTSD either with talk therapy or with drugs, or discontinuing treatment because of inability to tolerate psychotherapy or drug therapy.
  • Are at least 18 years old;
  • Must be generally healthy;
  • Must sign a medical release for the investigators to communicate directly with their therapist and doctors;
  • Are willing to refrain from taking any psychiatric medications during the study period;
  • Willing to follow restrictions and guidelines concerning consumption of food, beverages, and nicotine the night before and just prior to each experimental session;
  • Willing to remain overnight at the study site;
  • Agree to have transportation other than driving themselves home or to where they are staying after the integrative session on the day after the MDMA session;
  • Are willing to be contacted via telephone for all necessary telephone contacts;
  • Must have a negative pregnancy test if able to bear children, and agree to use an effective form of birth control;
  • Must provide a contact in the event of a participant becoming suicidal;
  • Are proficient in speaking and reading English;
  • Agree to have all clinic visit sessions recorded to audio and video
  • Agree not to participate in any other interventional clinical trials during the duration of this study.

Exclusion

  • Are pregnant or nursing, or if a woman who can have children, those who are not practicing an effective means of birth control;
  • Weigh less than 48 kg;
  • Are abusing illegal drugs;
  • Have used ecstasy (material representing itself as MDMA) more than 5 times or at least once in the last 6 months;
  • Are unable to give adequate informed consent;
  • Upon review of past and current drugs/medication must not be on or have taken a medication that is exclusionary;
  • Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation.

Key Trial Info

Start Date :

November 10 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 2 2016

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT01211405

Start Date

November 10 2010

End Date

August 2 2016

Last Update

June 5 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Offices of Michael Mithoefer

Mt. Pleasant, South Carolina, United States, 29464-4345